한국어
English
日本語
中文(简体)
Balbesajeng 3 mg (Erdafitinib)
3mg
Tablet · Prescription medication
Korea Janssen Co., Ltd.
Erdafitinib is an anticancer ingredient used for the treatment of cancers with FGFR gene mutations.
MFDS ingredient code M283261
Erdafitinib is an anticancer ingredient that inhibits the FGFR (Fibroblast Growth Factor Receptor) target. It is primarily used to suppress the growth and division of cancer cells in cancer patients with FGFR gene mutations.
Erdafitinib binds to the FGFR protein on the surface of cancer cells, blocking its signaling. This reduces the signals necessary for cancer cell proliferation and survival, producing an anti-cancer growth effect.
Approved uses differ by product. Check each product's information for its actual use.
Erdafitinib is distinguished from other similar anticancer drugs by its selective inhibition of FGFR receptors. It is especially used as a personalized therapy for patients in whom FGFR gene mutations have been confirmed.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.
